SAN ANTONIO -- Peanut oral immunotherapy (OIT) at maintenance doses 10 times lower than conventional dosing may be an effective strategy for desensitizing peanut-allergic patients, according to ...
image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...
rapid and sustained relief in CSU symptoms in a dose-dependent manner. favorable safety profile, no statistically significant difference in adverse events were found between LP-003 and placebo groups.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results